CA3052071A1 - Inhibiteurs de thiol isomerases et leur utilisation - Google Patents

Inhibiteurs de thiol isomerases et leur utilisation Download PDF

Info

Publication number
CA3052071A1
CA3052071A1 CA3052071A CA3052071A CA3052071A1 CA 3052071 A1 CA3052071 A1 CA 3052071A1 CA 3052071 A CA3052071 A CA 3052071A CA 3052071 A CA3052071 A CA 3052071A CA 3052071 A1 CA3052071 A1 CA 3052071A1
Authority
CA
Canada
Prior art keywords
disease
zafirlukast
thiol
extracellular
inhibitor compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3052071A
Other languages
English (en)
Inventor
Daniel Kennedy
Jonathan Gibbins
Lisa-Marie HOLBROOK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western New England University
Original Assignee
Western New England University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western New England University filed Critical Western New England University
Priority to CA3282526A priority Critical patent/CA3282526A1/en
Publication of CA3052071A1 publication Critical patent/CA3052071A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode d'administration à un patient en ayant besoin d'une quantité thérapeutiquement efficace d'un composé inhibiteur de thiol isomérase extracellulaire en vue de traiter ou de prévenir une maladie ou un état pathologique influencé par l'activité d'une ou de plusieurs thiol isomérases extracellulaires (par exemple, protéine disulfure isomérase, ERp5, ERp57, ERp72 et thiorédoxine). La maladie ou l'état pathologique comprend une thrombose artérielle, une thrombose veineuse, une maladie thrombotique, un cancer, une maladie infectieuse, une maladie virale, un trouble immunitaire, une inflammation, une maladie neurologique et un trouble neurodégénératif.
CA3052071A 2017-01-30 2018-01-29 Inhibiteurs de thiol isomerases et leur utilisation Pending CA3052071A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3282526A CA3282526A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451858P 2017-01-30 2017-01-30
US62/451,858 2017-01-30
PCT/US2018/015694 WO2018140858A1 (fr) 2017-01-30 2018-01-29 Inhibiteurs de thiol isomérases et leur utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3282526A Division CA3282526A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Publications (1)

Publication Number Publication Date
CA3052071A1 true CA3052071A1 (fr) 2018-08-02

Family

ID=62978426

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3052071A Pending CA3052071A1 (fr) 2017-01-30 2018-01-29 Inhibiteurs de thiol isomerases et leur utilisation
CA3282526A Pending CA3282526A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3282526A Pending CA3282526A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Country Status (6)

Country Link
US (2) US11872210B2 (fr)
EP (1) EP3585809B1 (fr)
JP (3) JP7272655B2 (fr)
BR (1) BR112019015721A2 (fr)
CA (2) CA3052071A1 (fr)
WO (1) WO2018140858A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164874A1 (fr) 2018-02-20 2019-08-29 Western New England University Inhibiteurs de thiol isomérases pour le traitement et la prévention d'allergies alimentaires, de maladies allergiques et de maladies inflammatoires
CN113289020B (zh) * 2021-05-17 2023-04-18 福州大学 蛋白质二硫键异构酶小分子抑制剂及其应用
CA3219671A1 (fr) 2021-05-19 2022-11-24 Thomas Christian Lines Compositions contenant de la quercetine destinees a etre utilisees dans le traitement de la sclerose laterale amyotrophique
EP4518852A1 (fr) * 2022-05-06 2025-03-12 Quercis Pharma AG Méthode de traitement de cancers et de maladies neurologiques à l'aide de compositions contenant de la quercétine
WO2024039822A1 (fr) * 2022-08-19 2024-02-22 Western New England University Inhibiteurs de thiol isomérases ; leur préparation ; et leurs procédés d'utilisation
WO2025094946A1 (fr) * 2023-10-30 2025-05-08 国立大学法人東海国立大学機構 Anticorps ou fragment de liaison à l'antigène de celui-ci, kit pour le traitement du cancer, et composition pour le traitement du cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4985465A (en) 1989-07-14 1991-01-15 Hendler Sheldon S Method for inhibiting viral and retroviral infections
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9027018D0 (en) 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
DK1817301T3 (da) * 2004-11-22 2012-02-27 Lilly Co Eli Forstærkere af glutamat-receptorer
KR100649009B1 (ko) 2004-12-30 2006-11-27 동부일렉트로닉스 주식회사 시모스 이미지 센서의 광감지 소자 및 그의 제조방법
WO2006127525A2 (fr) 2005-05-20 2006-11-30 Jack Arbiser Inhibiteurs de proteasome et utilisations de ceux-ci
US8337814B2 (en) 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
WO2008033466A2 (fr) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions et procédés pour le traitement de maladies virales
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
DE102007001804A1 (de) 2007-01-12 2008-07-17 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von GABAB-Rezeptor selektiven Agonisten zur Behandlung entzündlicher Hauterkrankungen
EP2269076A4 (fr) 2008-03-14 2011-04-06 Nat Jewish Health Procédés pour déterminer la sensibilité à un traitement avec des modificateurs de leucotriène
US8980917B2 (en) 2008-06-12 2015-03-17 The Johns Hopkins University Methods for treating or preventing brain infections
WO2013055674A1 (fr) 2011-10-10 2013-04-18 The University Of Toledo Méthode de traitement d'infections
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
CA2901413A1 (fr) 2013-03-13 2014-10-09 Bruce Chandler May Utilisation de levocetirizine et de montelukast dans le traitement de la vascularite
US9616056B2 (en) 2013-03-15 2017-04-11 Institute For Cancer Research Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma
RU2667644C2 (ru) * 2013-04-22 2018-09-21 Тотиги Инститьют Оф Клиникал Патолоджи Противоопухолевое средство
US20160145209A1 (en) * 2013-06-21 2016-05-26 The Broad Institute, Inc. Compounds and compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
GB201321089D0 (en) 2013-11-29 2014-01-15 Univ East London Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
WO2016118639A1 (fr) * 2015-01-20 2016-07-28 The Trustees Of Columbia University In The City Of New York Oxydants de la pdi à petite molécule et leur utilisation
JP6528314B2 (ja) * 2015-03-20 2019-06-12 国立大学法人山口大学 Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤

Also Published As

Publication number Publication date
US20210008032A1 (en) 2021-01-14
JP7272655B2 (ja) 2023-05-12
EP3585809B1 (fr) 2025-07-02
EP3585809A1 (fr) 2020-01-01
JP2020514411A (ja) 2020-05-21
JP2024161023A (ja) 2024-11-15
WO2018140858A1 (fr) 2018-08-02
CA3282526A1 (en) 2025-10-30
EP3585809A4 (fr) 2021-02-24
US20240108600A1 (en) 2024-04-04
US11872210B2 (en) 2024-01-16
JP2023030014A (ja) 2023-03-07
BR112019015721A2 (pt) 2020-03-24

Similar Documents

Publication Publication Date Title
US20240108600A1 (en) Thiol isomerases inhibitors and use thereof
CA3183081A1 (fr) Polytherapie pour le traitement du cancer
US11364242B2 (en) Treatment agents for inhibiting HIV and cancer in HIV infected patients
JP7640454B2 (ja) Ｌｒｒｋ２の野生型および変異型の分解誘導剤
US20140296255A1 (en) Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
CA3220039A1 (fr) Derives d'uree pouvant etre utilises pour traiter le cancer
WO2009063202A2 (fr) Utilisation de composés antagonistes de crth2
US12152036B2 (en) Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists
CA2642587A1 (fr) Composes et methodes pour traiter un accident cerebrovasculaire
TW201235040A (en) Drug therapy for preventing or treating glaucoma
JP2024533975A (ja) Ｐｉ３ｋアイソフォームアルファを阻害する化合物及びがんを処置するための方法
WO2006137510A1 (fr) Agent pour réduire le saignement lors de troubles cérébrovasculaires
RU2452479C2 (ru) Терапевтический агент при нарушении мочевыделения
Golino et al. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions
Kubo et al. Lysosomal trapping is present in retinal capillary endothelial cells: insight into its influence on cationic drug transport at the inner blood–retinal barrier
US10906876B2 (en) Tetrahydroisoquinolines as selective NADPH oxidase 2 inhibitors
WO2007089774A2 (fr) Compositions et procédés de traitement de troubles cognitifs
WO2023067550A1 (fr) Composés inhibiteurs allostériques pour surmonter la résistance d'un cancer
WO2014119823A9 (fr) Composition pharmaceutique destinée à réduire ou inhiber la formation de cicatrices, contenant bmp-7 et un agent de dilution
HK40091747A (zh) 用於治疗癌症的组合疗法
Potpara et al. Novel Oral Anticoagulants for Thromboprophylaxis in Non-Valvular Atrial Fibrillation: Focus on Randomized Clinical Trials

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250329

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250329

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250425

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250812

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250818

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250924

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318